Detalhe da pesquisa
1.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438627
2.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(5): 1008-1011, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38425185
3.
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Am J Hematol
; 98(5): 770-783, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814396
4.
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
Am J Hematol
; 97(4): 390-400, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015307
5.
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.
Eur J Haematol
; 106(1): 58-63, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32909297
6.
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Blood
; 132(7): 694-706, 2018 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29907599
7.
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
BMC Cancer
; 18(1): 1008, 2018 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30342509
8.
Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.
Eur J Haematol
; 2018 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603799
9.
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
Am J Hematol
; 92(9): 885-891, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28543356
10.
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Br J Haematol
; 164(6): 822-33, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24372512
11.
Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome.
Hematology
; 29(1): 2311600, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38329272
12.
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR).
Cancers (Basel)
; 15(3)2023 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765918
13.
The impact of COVID-19 and socioeconomic status on psychological distress in cancer patients.
Int J Clin Health Psychol
; 23(4): 100404, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37663044
14.
Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy : Breaking a dangerous bond.
Wien Klin Wochenschr
; 134(11-12): 478-482, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305139
15.
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine.
Blood Cancer Discov
; 3(6): 502-515, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125297
16.
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Haematologica
; 96(1): 163-6, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20934998
17.
Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM.
Cancers (Basel)
; 13(23)2021 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34885001
18.
Pathway-Directed Therapy in Multiple Myeloma.
Cancers (Basel)
; 13(7)2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33916289
19.
The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond.
Cancers (Basel)
; 13(18)2021 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34572927
20.
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
J Cancer Res Clin Oncol
; 147(1): 205-212, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32683487